Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

April 19, 2021April 19, 2021

Greater Support for Dementia Patients Needed Across Europe, Report Says

News

Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according to a new report. The report, “Dementia Monitor 2020,” was ... Read more

March 29, 2021March 29, 2021

Sargramostim, Immune System Activator, May Aid Cognition, Small Trial Finds

News

People with mild-to-moderate Alzheimer’s disease treated for three weeks with sargramostim, a medication that activates the immune system, showed improvements in cognition in a small clinical trial. These results support further ... Read more

March 3, 2021March 3, 2021

Pivotal Phase 3 Trials of Oral Simufilam Planned for Year’s End

News

Cassava Sciences plans to launch two Phase 3 clinical trials evaluating the efficacy of simufilam, its investigational oral treatment for Alzheimer’s disease, in the second half of this year, the ... Read more

February 15, 2021February 15, 2021

Oral Simufilam Found to Improve Cognition, Behavior After 6 Months’ Use

News

Simufilam, an investigational oral medication being developed by Cassava Sciences, improved cognition and behavior in people with Alzheimer’s disease after six months of dosing in a clinical trial, interim data ... Read more

January 27, 2021January 27, 2021

Patients, Caregivers Urged to Get COVID-19 Vaccines ASAP

News

People with Alzheimer’s disease, as well as their caregivers, are being urged — on social media and via press releases — to get COVID-19 vaccines as soon as possible. That’s ... Read more

January 20, 2021January 20, 2021

New Technique May Enable Early Diagnosis of Alzheimer’s

News

A newly developed technique could make it easier to measure very small concentrations of molecules, which may have implications in early diagnostic testing for Alzheimer’s and other diseases. The technique ... Read more

November 18, 2020November 18, 2020

Last Participant Finishes PEGASUS Clinical Trial, Results Expected Next Year

News

The last participant has completed the planned 24 weeks in the Phase 2 PEGASUS clinical trial, which is assessing the safety and biological activity of Amylyx Pharmaceuticals‘ investigational therapy AMX0035 ... Read more

November 16, 2020November 16, 2020

FDA Clears Neuraly to Begin Phase 2 Trial of NLY01 in Alzheimer’s Patients

News

The U.S. Food and Drug Administration has given clearance for a Phase 2B clinical trial to evaluate the safety, tolerability, and efficacy of Nueraly‘s investigational therapy NLY01 in people with ... Read more

November 11, 2020November 11, 2020

FDA Committee Votes Do Not Support Aducanumab as Effective Treatment

News

An advisory arm of the U.S. Food and Drug Administration (FDA) is recommending that available clinical data on aducanumab (BIIB037) does not support the effectiveness of this investigational therapy in ... Read more

October 28, 2020October 28, 2020

First Patient Dosed in Biomarker Study of Oral Alzheimer’s Therapy, ALZ-801

News

A first patient has been dosed in a Phase 2 trial evaluating the effects of ALZ-801 on disease-related biomarkers in people with early Alzheimer’s disease, who have a specific genetic ... Read more